SKYE: חוב כולל להון Skye Bioscience

The Skye Bioscience, Inc. (SKYE) price chart shows the separate_debt_total_eq metric at 0.00. Skye Bioscience, Inc. (SKYE) is integrating ESG principles into cannabinoid development, minimizing environmental impact and adhering to bioethics. Management relies on scientific rigor when developing treatments for metabolic disorders. The business operates within the strict regulatory frameworks of the FDA and DEA, creating therapies for obesity and glaucoma for active volunteer groups.

Skye Bioscience, Inc. (SKYE) is investing in advanced developments of cannabinoid drugs for vision treatment. Analyzing the financial leverage trend via the debt-to-equity ratio, we assess the proportion of borrowed funds relative to equity assets. A low ratio confirms high business autonomy and price stability. This metric demonstrates the company's ability to provide scientists with stable funding without a critical debt burden. A balanced level of leverage guarantees the development of unique medications without the risk of bankruptcy.